IgA nephropathy (IgAN) is the most common primary glomerulonephritis in developed countries and a leading cause of chronic kidney disease. IgAN is a mesangial proliferative glomerulonephritis characterized by diffuse mesangial deposition of IgA, often accompanied by the deposition of IgG and the C3 component of complement in a similar distribution. This condition is in most cases oligosymptomatic, often discovered coincidentally. Currently, there is no specific treatment available for IgAN and the use of immunosuppression therapy is debated. Due to immune-mediated pathogenic nature of IgAN, therapy with mycophenolate mofetil (MMF), a potent immunosuppressive agent, could be effective in patients at risk for progressive disease. In this paper, we discuss the case of an IgAN patient treated with MMF at our center, followed by a review of the literature and our previous experience on the potential renoprotective effects of MMF in IgAN patients with different clinical presentation, despite adequate angiotensin blockade and steroid therapy.

Baraldi, O., Comai, G., Cuna, V., Cappuccilli, M., Serra, C., Ronco, C., et al. (2017). Mycophenolate Mofetil: A Possible Alternative Treatment for IgA Nephropathy. CONTRIBUTIONS TO NEPHROLOGY, 190, 108-116 [10.1159/000468955].

Mycophenolate Mofetil: A Possible Alternative Treatment for IgA Nephropathy

BARALDI, OLGA;COMAI, GIORGIA;CUNA, VANIA;CAPPUCCILLI, MARIA;SERRA, CARLA;RONCO, CLAUDIO;LA MANNA, GAETANO
2017

Abstract

IgA nephropathy (IgAN) is the most common primary glomerulonephritis in developed countries and a leading cause of chronic kidney disease. IgAN is a mesangial proliferative glomerulonephritis characterized by diffuse mesangial deposition of IgA, often accompanied by the deposition of IgG and the C3 component of complement in a similar distribution. This condition is in most cases oligosymptomatic, often discovered coincidentally. Currently, there is no specific treatment available for IgAN and the use of immunosuppression therapy is debated. Due to immune-mediated pathogenic nature of IgAN, therapy with mycophenolate mofetil (MMF), a potent immunosuppressive agent, could be effective in patients at risk for progressive disease. In this paper, we discuss the case of an IgAN patient treated with MMF at our center, followed by a review of the literature and our previous experience on the potential renoprotective effects of MMF in IgAN patients with different clinical presentation, despite adequate angiotensin blockade and steroid therapy.
2017
Baraldi, O., Comai, G., Cuna, V., Cappuccilli, M., Serra, C., Ronco, C., et al. (2017). Mycophenolate Mofetil: A Possible Alternative Treatment for IgA Nephropathy. CONTRIBUTIONS TO NEPHROLOGY, 190, 108-116 [10.1159/000468955].
Baraldi, Olga; Comai, Giorgia; Cuna, Vania; Cappuccilli, Maria; Serra, Carla; Ronco, Claudio; La Manna, Gaetano
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/603911
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 3
social impact